Perini Paola, Calabrese Massimiliano, Rinaldi Luciano, Gallo Paolo
Multiple Sclerosis Centre-Veneto Region, Department of Neuroscience, University Hospital, Via Giustiniani 5, 35128, Padova, Italy.
Neurol Sci. 2008 Sep;29 Suppl 2:S233-4. doi: 10.1007/s10072-008-0947-9.
Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNbeta) have also been successfully applied to treat IFNbeta-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases.
免疫调节药物（IMA）无反应性多发性硬化症（MS）可迅速发展为严重且不可逆的残疾。用适当的免疫抑制疗法治疗这些患者可能是阻止疾病活动和进展的一个机会。基于环磷酰胺（Cyc）的强化免疫抑制已成功用于治疗快速恶化的、IMA难治性MS患者。将Cyc与干扰素β（IFNβ）联合的治疗方案也已成功应用于治疗IFNβ无反应性MS。目前正在针对治疗严重自身免疫性疾病的临床试验中研究Cyc与其他免疫调节药物或单克隆抗体的联合应用。
